Capitulo1
Capitulo2
Capitulo3
Capitulo4
Capitulo5
Capitulo6
Capitulo7
Capitulo8
Capitulo2
Capitulo3
Capitulo11
Capitulo12
Capitulo13
Capitulo14
Capitulo15
Capitulo16
Capitulo17

1. Klein R, BE Klein, Moss SE: Visual impairment in diabetes. Ophthalmology 1984, 91:1–9.

2. Klein R, Klein BE, Moss SE, Cruickshanks KJ:The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995, 102:7–16.

3. Javitt JC, Aiello LP, Bassi LJ, et al.: Detecting and treating retinopathy in patients with type I diabetes mellitus. Savings associated with improved implementation of current guidelines. American Academy of Ophthalmology. Ophthalmology 1991, 98:1565–1573.

4. Javitt JC, Aiello LP, Chiang Y, et al.: Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care 1994, 17:909–917.

5. Javitt JC, Aiello LP: Cost-effectiveness of detecting and treating diabetic retinopathy [see comments]. Ann Intern Med 1996, 124:164–169.

6. Javitt, JC, Canner JK, Sommer A: Cost effectiveness of current approaches to the control of retinopathy in type 1 diabetics. Ophthalmology 1989, 96:255–264.

7. Kahn HA, Hiller R: Blindness caused by diabetic retinopathy. Am J Ophthalmol 1974, 78:58–67.

8. Palmberg PF: Diabetic retinopathy. Diabetes 1977, 26:703–709.

9. The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus [see comments]. N Engl J Med 1993, 329:977–986.

10. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995, 44:968–983.

11. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. Am J Ophthalmol 2000, 129(5):704–705.

12. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes control and complications trial.The Diabetes Control and Complications Trial Research Group [see comments]. JAMA 1996 276:1409–1415; published erratum, JAMA 1997, 278:25.

13. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 1995, 18:1468–1478.

14. Ferris FL: How effective are treatments for diabetic retinopathy? JAMA 1993, 269:1290–1291.

15. Aiello LP, Gardner TW, King GL, et al.: Diabetic retinopathy: technical review. Diabetes Care 1998, 21:143–156.

16. National Diabetes Data Group: Diabetes in America.Washington, DC: US Government Printing Office; 1995.

17. Bursell SE, Clermont AC, Kinsley BT, et al.: Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Am J Physiol 1996, 270:R61–R70.

18. Krolewski AS,Warram JH, Rand LI, et al.: Risk of proliferative diabetic retinopathy in juvenile-onset type 1 diabetes: a 40-yr follow-up study. Diabetes Care 1984, 9:443–452.

19. Klein R, Klein BE, Moss SE, et al.:The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984, 102:520–536.

20. Klein R, Moss SE, Klein BE, et al.: New management concepts for timely diagnosis of diabetic retinopathy treatable by photocoagulation. Diabetes Care 1987, 10:633–638.

21. American Academy of Pediatrics: Screening for retinopathy in the pediatric patient with type 1 diabetes mellitus. Pediatrics 1998, 101:313–314.

22. Klein BE, Moss SE, Klein R: Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990, 13:34–40.

23. The Early Treatment Diabetic Retinopathy Study Research Group: Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 1991, 98:786–806.

24. The Early Treatment Diabetic Retinopathy Study Research Group: Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991, 98:766–785.

25. The Diabetic Retinopathy Study Research Group: Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 1981, 88:583–600.

26. The Diabetic Retinopathy Study Research Group: Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. Int Ophthalmol Clin 1987, 27:239–253.

27. The Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985, 103:1796–1806.

28. Cavallerano J: Diabetic retinopathy. Clinical Eye and Vision Care 1990, 2:4–14.

29. Ferris F: Early photocoagulation in patients with either type 1 or type 2 diabetes. Trans Am Ophthalmol Soc 1996, 94:505–537.

30. The Diabetes Control and Complications Trial Research Group:The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. Arch Ophthalmol 1995, 113:36–51.

31. The Diabetic Retinopathy Vitrectomy Study Research Group: Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 4. Ophthalmology 1988, 95:1321–1334.

32. Aiello LP, Cahill MT,Wong JS: Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 2001, 132(5):760–776.

33. Michaelson IC:The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK 1948, 68:137–180.

34. Aiello LP, Northrup JM, Keyt BA: Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995, 113:1538–1544.

35. Aiello LP, Avery RL, Arrigg PG, et al.: Vascular endothelial growth factorin ocular fluid of patients with diabetic retinopathy and other retinaldisorders [see comments]. N Engl J Med 1994, 331:1480–1487.

36. Aiello LP, Pierce EA, Foley ED, et al.: Suppression of retinal neovascularizationin vivo by inhibition of vascular endothelial growth factor (VEGF) usingsoluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995,92:10457–10461.

37. Adamis AP, Shima DT,Tolentino MJ, et al.: Inhibition of vascular endothelialgrowth factor prevents retinal ischemia-associated iris neovascularizationin a nonhuman primate. Arch Ophthalmol 1996, 114:66–71.

38. Robinson GS, Pierce EA, Rook SL, et al.: Oligodeoxynucleotides inhibitretinal neovascularization in a murine model of proliferative retinopathy.Proc Natl Acad Sci USA 1996, 93:4851–4856.

39. Smith LE,Wesolowski E, McLellan A, et al.: Oxygen-induced retinopathyin the mouse. Invest Ophthalmol Vis Sci 1994, 35:101–111.

40. Aiello LP: Vascular endothelial growth factor. 20th-century mechanisms,21st-century therapies. Invest Ophthalmol Vis Sci 1997, 38:1647–1652.

41. Gaede P, Vedel P, Parving HH, Pedersen O: Intensified multifactorialintervention in patients with type 2 diabetes mellitus andmicroalbuminuria: the Steno type 2 randomised study. Lancet 1999,353:617–622.

 voltar